Evaluation of RETmRNA expression in malignant tumors of the salivary glands


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Treatment of locally advanced, recurrent or metastatic forms of malignant tumors of the salivary gland is a difficult task for clinical oncologists. Tumors of the salivary glands are insensitive to radiation and drug therapy. Objective. Evaluation of the frequency of RET mRNA expression in malignant tumors of the salivary glands as a possible prognostic factor for the course of the disease. Methods. The source of mRNA was archived pathological morphological samples of tumor tissue. Evaluation of mRNA expression of the RET kinase domain was performed using real-time polymerase chain reaction. Results. RET expression was detected in 13 of 48 cases, which amounted to 27.08% of the examined tumors (in other words, in almost one third of the examined samples). The expression level ranged from 0 to 0.205. Conclusion. The results obtained suggest that the RET mRNA expression level can be used not only as a prognostic, but also a predictive factor of the effectiveness of the multi-kinase inhibitors in this cohort of patients (after conducting prospective randomized trials).

全文:

受限制的访问

作者简介

S. Kutukova

City Clinical Oncology Dispensary; Pavlov First St. Petersburg State Medical University

Email: dr.s.kutukova@gmail.com
PhD, Oncologist, Chemotherapy Department (№ 11), City Clinical Oncology Dispensary; Associate Professor, Department of Suigical Dentistry and Maxillofacial Surgery 56, Veteranov Avenue, St. Petersburg, 198255, Russian Federation

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Yu. Ivaskova

City Clinical Oncology Dispensary; Pavlov First St. Petersburg State Medical University

St. Petersburg, Russia

N. Belyak

City Clinical Oncology Dispensary; St. Petersburg State University

St. Petersburg, Russia

A. Razumova

Pavlov First St. Petersburg State Medical University

St. Petersburg, Russia

参考

  1. Van Dijk B.A., Gatta G., Capocaccia R., et aI., RARECARE Working group. RARECARE Working group. Rare cancers of the head and neck area in Europe. Eur J Cancer. 2012;48:783e96. doi: 10.1016/j.ejca.2011.08.021.
  2. Barnes L., Evenson J.W., Reichart P, Sidransky D. Salivary glands. In: World Health Organization classification of tumours: pathology & genetics of head and neck tumours. Lyon, France: IARC. Press, 2005. P 209e81.
  3. Storey M.R., Garden A.S., Morrison W.H., et al. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys. 2001;51:952e8.
  4. Белоус Т.А. Эпителиальные опухоли слюнных желез. Дис. канд. мед. наук. М., 1978. [Belous T.A. Epithelial tumors salivary glands. Diss. Cand. of Med. Sciences. M., 1978. (In Russ.)].
  5. Holmes T, Das R., Low D., et al. IMRT Documentation Working Group. American Society of Radiation Oncology recommendation for documenting intensity-modulated radiation therapy treatments. Int J Radiat Oncol Biol Phys. 2009;74(5):1311-18.
  6. Lee N.Y., O'Meara W., Chan K., et al. Concurrent chemotherapy and intensity- modulated radiotherapy for locoregiolnaly advanced laryngeal and hypopharyngeal. Int J Radiat. Oncol Biol Phys. 2007;69(2): 459-68. Doi: 10.1016/j. ijrobp.2007.03.013.
  7. NCCN Clinical Practice Guidelines in Oncology. Salivary Gland Tumors. Head and Neck Cancer, 2019. Version 1. Part 1.
  8. Laurie S.A., Ho A.L., Fury M.G., et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet. Oncol. 2011;12:815e24. doi: 10.1016/S1470-2045(10)70245-X
  9. Eneroth C.M. Salivary gland tumors in the parotid gland, submandibular gland, and the palate region. Cancer. 1971;27:1415-18.
  10. Вайрадян В.Т., Мудунов А.М., Ермилова В.Д. и др. Анализ результатов лечения больных со злокачественными опухолями слюнных желез. Опухоли головы и шеи, 2016;6(3):42-52
  11. Bunone G., Uggeri M., Mondellini P, et al. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res. 2000; 60:2845-49.
  12. Locati L.D., Perrone F, Cortelazzi B., et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. Eur J Cancer. 2016;69:158-65. Doi: https://doi.org/10.1016/j.ejca. 2016.09.022.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019